GLAXO - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.8
| Stock Code | GLAXO | Market Cap | 40,304 Cr. | Current Price | 2,377 ₹ | High / Low | 3,516 ₹ |
| Stock P/E | 40.5 | Book Value | 101 ₹ | Dividend Yield | 1.77 % | ROCE | 62.6 % |
| ROE | 46.4 % | Face Value | 10.0 ₹ | DMA 50 | 2,501 ₹ | DMA 200 | 2,606 ₹ |
| Chg in FII Hold | -0.16 % | Chg in DII Hold | -0.05 % | PAT Qtr | 277 Cr. | PAT Prev Qtr | 253 Cr. |
| RSI | 36.2 | MACD | -29.9 | Volume | 24,466 | Avg Vol 1Wk | 37,066 |
| Low price | 2,220 ₹ | High price | 3,516 ₹ | PEG Ratio | -2.04 | Debt to equity | 0.02 |
| 52w Index | 12.1 % | Qtr Profit Var | 21.3 % | EPS | 58.8 ₹ | Industry PE | 27.2 |
📊 Analysis: GlaxoSmithKline Pharmaceuticals shows exceptional efficiency with ROCE at 62.6% and ROE at 46.4%, reflecting strong profitability and capital utilization. The company maintains a nearly debt-free balance sheet (0.02 debt-to-equity), which adds financial stability. However, the P/E of 40.5 is significantly higher than the industry average of 27.2, suggesting overvaluation. The PEG ratio of -2.04 indicates weak growth prospects relative to valuation. Dividend yield of 1.77% provides moderate income support. Technical indicators (RSI 36.2, MACD -29.9) show oversold conditions, with the stock trading below both DMA 50 and DMA 200, signaling bearish momentum.
💰 Entry Price Zone: Considering current weakness and oversold RSI, the ideal entry zone is ₹2,250–₹2,350, closer to the 52-week low of ₹2,220. This range offers better risk-reward compared to current levels.
📈 Exit / Holding Strategy: For long-term investors, Glaxo’s strong ROE and ROCE justify holding for 3–5 years. Exit strategy should involve partial profit booking near ₹3,200–₹3,400 if valuations expand again. Dividend yield supports holding, but monitor PEG ratio and institutional activity (recent FII/DII decline) for signals of weakness.
✅ Positive
- High ROCE (62.6%) and ROE (46.4%) indicate strong efficiency.
- Debt-free balance sheet ensures financial safety.
- Quarterly PAT growth of 21.3% shows earnings momentum.
- Dividend yield of 1.77% adds stability.
⚠️ Limitation
- PEG ratio of -2.04 suggests poor growth prospects.
- P/E of 40.5 is high compared to industry average (27.2).
- Stock trading below DMA 50 and DMA 200 indicates weak trend.
📉 Company Negative News
- Decline in institutional holdings (FII -0.16%, DII -0.05%).
- Stock corrected sharply from 52-week high of ₹3,516.
📈 Company Positive News
- Quarterly PAT improved from ₹253 Cr. to ₹277 Cr.
- EPS of ₹58.8 reflects steady profitability.
- Industry-leading efficiency metrics (ROCE, ROE).
🏭 Industry
- Pharmaceutical sector benefits from consistent demand and global healthcare needs.
- Industry PE of 27.2 reflects moderate optimism in the sector.
📝 Conclusion
GlaxoSmithKline Pharmaceuticals is a fundamentally strong company with high efficiency and profitability. However, valuations are stretched as reflected in the high P/E and negative PEG ratio. Ideal entry is around ₹2,250–₹2,350. Long-term investors can hold for 3–5 years, supported by strong ROE/ROCE, with partial profit booking near ₹3,200–₹3,400 if valuations expand again.